Chiranjib Chakraborty, Manojit Bhattacharya, Sang-Soo Lee, Zhi-Hong Wen, Yi-Hao Lo
{"title":"The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges","authors":"Chiranjib Chakraborty, Manojit Bhattacharya, Sang-Soo Lee, Zhi-Hong Wen, Yi-Hao Lo","doi":"10.1016/j.omtn.2024.102295","DOIUrl":null,"url":null,"abstract":"Due to the transformation of artificial intelligence (AI) tools and technologies, AI-driven drug discovery has come to the forefront. It reduces the time and expenditure. Due to these advantages, pharmaceutical industries are concentrating on AI-driven drug discovery. Several drug molecules have been discovered using AI-based techniques and tools, and several newly AI-discovered drug molecules have already entered clinical trials. In this review, we first present the data and their resources in the pharmaceutical sector for AI-driven drug discovery and illustrated some significant algorithms or techniques used for AI and ML which are used in this field. We gave an overview of the deep neural network (NN) models and compared them with artificial NNs. Then, we illustrate the recent advancement of the landscape of drug discovery using AI to deep learning, such as the identification of drug targets, prediction of their structure, estimation of drug-target interaction, estimation of drug-target binding affinity, design of drug, prediction of drug toxicity, estimation of absorption, distribution, metabolism, excretion, toxicity; and estimation of drug-drug interaction. Moreover, we highlighted the success stories of AI-driven drug discovery and discussed several collaboration and the challenges in this area. The discussions in the article will enrich the pharmaceutical industry.","PeriodicalId":18821,"journal":{"name":"Molecular Therapy. Nucleic Acids","volume":"60 1","pages":""},"PeriodicalIF":6.5000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy. Nucleic Acids","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtn.2024.102295","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Due to the transformation of artificial intelligence (AI) tools and technologies, AI-driven drug discovery has come to the forefront. It reduces the time and expenditure. Due to these advantages, pharmaceutical industries are concentrating on AI-driven drug discovery. Several drug molecules have been discovered using AI-based techniques and tools, and several newly AI-discovered drug molecules have already entered clinical trials. In this review, we first present the data and their resources in the pharmaceutical sector for AI-driven drug discovery and illustrated some significant algorithms or techniques used for AI and ML which are used in this field. We gave an overview of the deep neural network (NN) models and compared them with artificial NNs. Then, we illustrate the recent advancement of the landscape of drug discovery using AI to deep learning, such as the identification of drug targets, prediction of their structure, estimation of drug-target interaction, estimation of drug-target binding affinity, design of drug, prediction of drug toxicity, estimation of absorption, distribution, metabolism, excretion, toxicity; and estimation of drug-drug interaction. Moreover, we highlighted the success stories of AI-driven drug discovery and discussed several collaboration and the challenges in this area. The discussions in the article will enrich the pharmaceutical industry.
由于人工智能(AI)工具和技术的变革,AI 驱动的药物发现已走到前沿。它缩短了时间,减少了开支。由于这些优势,制药行业正专注于人工智能驱动的药物发现。一些药物分子已经利用基于人工智能的技术和工具被发现,一些新发现的人工智能药物分子已经进入临床试验阶段。在这篇综述中,我们首先介绍了制药领域用于人工智能驱动药物发现的数据及其资源,并说明了该领域使用的一些重要的人工智能和 ML 算法或技术。我们概述了深度神经网络(NN)模型,并将其与人工神经网络进行了比较。然后,我们阐述了利用人工智能和深度学习进行药物发现的最新进展,如药物靶点的识别、药物靶点结构的预测、药物与靶点相互作用的估计、药物与靶点结合亲和力的估计、药物设计、药物毒性的预测、吸收、分布、代谢、排泄、毒性的估计以及药物与药物相互作用的估计。此外,我们还重点介绍了人工智能驱动药物发现的成功案例,并讨论了这一领域的若干合作与挑战。文章中的讨论将丰富制药行业的内容。
期刊介绍:
Molecular Therapy Nucleic Acids is an international, open-access journal that publishes high-quality research in nucleic-acid-based therapeutics to treat and correct genetic and acquired diseases. It is the official journal of the American Society of Gene & Cell Therapy and is built upon the success of Molecular Therapy. The journal focuses on gene- and oligonucleotide-based therapies and publishes peer-reviewed research, reviews, and commentaries. Its impact factor for 2022 is 8.8. The subject areas covered include the development of therapeutics based on nucleic acids and their derivatives, vector development for RNA-based therapeutics delivery, utilization of gene-modifying agents like Zn finger nucleases and triplex-forming oligonucleotides, pre-clinical target validation, safety and efficacy studies, and clinical trials.